Skip to main content

Table 5 Tolerability of NVP-based HAART among the three groups.

From: Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study

Tolerability outcomes Not receiving fluconazole Receiving fluconazole Pvalue
  (n = 225) 400 mg/week (n = 392) 200 mg/day (n = 69)  
On NVP-based HAART at six months 174 (77.3%) 309 (78.8%) 58 (84.1%) 0.532
Reasons of discontinuation     0.448
   Adverse events 26 (11.5%) 29 (7.4%) 3 (4.3%)  
Skin rashes 25/26 (96.2%) 26/29 (89.7%) 3 of 3 (100.0%)  
Hepatotoxicity 1/26 (2.8%) 3/29 (10.3%) -  
   Death 1 (0.4%) 8 (2.0%) -  
   Loss to follow-up 20 (8.9%) 39 (9.9%) 7 (10.1%)  
   Refer 4 (1.8%) 7 (1.8%) 1 (1.4%)